Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /templates/labohome22/functions.php on line 199




Badania oceniające dietę eliminacyjną z kontrolowanymi warunkami badania klinicznego (randomizacja, pojedyncza lub podwójnie zaślepiona próba, cross-over)


  1. Atkinson W et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53(10):1459-64
  2. Rees T et al. A prospective Audit of food intolerance among migraine patients in primary care clinical practice. Headache 2005
  3. Bentz S et al. Clinical relevance of IgG antibodies against food antigens in Crohn’s disease: a double-blind cross-over diet intervention study. Digestion. 2010;81(4):252-64
  4. Alpay K et al. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia. 2010;30(7):829-37
  5. Aydinlar et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache. 2013;53(3):514-25


Badania oceniające dietę eliminacyjną bez kontroli warunków badania klinicznego

  1. Hardman G and Hart G Dietary advice based on food‐specific IgG results Nutrition & Food Science 2007 IF=3,48
  2. Uzunısmaıl H et al. The effects of provocation by foods with raised IgG antibodies and additives on the course of Crohn’s disease: a pilot study. Turk J Gastroenterol. 2012;23(1):19-27. IF=0,78
  3. Arroyave H et al. Food allergy mediated by IgG antibodies associated with migraine in adults. Rev Alerg Mex. 2007;54(5):162-8. IF=0
  4. Virdee K et al. Food-specific IgG Antibody-guided Elimination Diets Followed by Resolution of Asthma Symptoms and Reduction in Pharmacological Interventions in Two Patients: A Case Report. Glob Adv Health Med. 2015 IF=0
  5. Matthews M Food Intolerance and its impact on chronic disease – badania nie były opublikowane w żadnym czasopiśmie.
  6. Yang CM and Li YQ The therapeutic effects of eliminating allergic foods according to food-specific IgG antibodies in irritable bowel syndrome. Zhonghua Nei Ke Za Zhi. 2007 Aug;46(8):641-3. IF=0
  7. Guo H et al. The value of eliminating foods according to food-specific immunoglobulin G antibodies in irritable bowel syndrome with diarrhoea. J Int Med Res. 2012;40(1):204-10. IF=1,11
  8. Lewis et al. Eliminating Immunologically-Reactive Foods from the Diet and its Effect on Body Composition and Quality of Life in Overweight Persons J Obes Weig los Ther 2012; 2:112. IF=0,941
  9. Lewis et al. A pilot study eliminating immunologically-reactive foods from the diet and its effect on symptomatology and quality of life in persons with chronic migraines and headaches Open Journal of Internal Medicine 2013; 3: 8-14. IF=0


Badania dotyczące nadwrażliwości pokarmowej typu III 

  1. Hon KL et al. Specific IgG and IgA of common foods in Chinese children with eczema: friend or foe. J Dermatolog Treat. 2014;b25(6):462-6. IF=1,87
  2. Kukkonen K et al. Ovalbumin-specific immunoglobulins A and G levels at age 2 years are associated with the occurrence of atopic disorders. Clin Exp Allergy. 2011;41:1414-21. IF=4,32
  3. Vance GH et al. Ovalbumin-specific immunoglobulin G and subclass responses through the first 5 years of life in relation to duration of egg sensitization and the development of asthma. Clin Exp Allergy. 2004;34:1542-9. IF=4,32
  4. Hvatum M et al. The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis. Gut. 2006 ;55(9):1240-7 IF= 14,66
  5. Severence EG et. al Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia. Neurobiol Dis. 2012 IF=5,11
  6. Severence EG et. al. Gastrointestinal inflammation and associated immune activation in schizophrenia Schizophr Res. 2012 IF=3,92
  7. Niehbur DW et al. Association between bovine casein antibody and new onset schizophrenia among US military personnel. Schizophr. Res. 2011 IF=3,92
  8. Severance et. al. Dietry antigens, epitope recognation, and immune complex formation In recent onset psychosis and long-term schizophernia. Schizophr.Res. 2011 IF=3,92
  9. Cai C et al. Serological investigation of food specific immunoglobulin G antibodies in patients with inflammatory bowel diseases. PLoS One. 2014 IF=3,53
  10. Wilders-Truschnig M et al. IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles. Exp Clin Endocrinol Diabetes. 2008 IF=1,76
  11. Zuo XL et al. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy 2007 IF=4,32
  12. Kumar R et al. Prevalence of food intolerance in bronchial asthma in India. Indian J Allergy Asthma Immunol 2013;27:121-8
  13. Magistris L et al. Antibodies against food antigens in patients with autistic spectrum disorders. Biomed Res Int. 2013;2013:729349 IF=2,134


Sceptyczne wyniki badań

  1. Ligaarden SC et al. IgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control study in the general population. BMC Gastroenterol. 2012 21;12:166 IF=2,36
  2. Mitchell N et al. Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. Nutr J. 2011;10:85 IF=2,6


Artykuły przeglądowe

  1. Karakuła-Juchnowicz H et al. The role of IgG hypersensitivity in the pathogenesis and therapy of depressive disorders. Nutr Neurosci. 2014 IF=2,11
  2. Mullin GE et al. Testing for food reactions: the good, the bad, and the ugly. Nutr Clin Pract. 2010 ;25(2):192-8 IF=2,11
  3. Gałecka M i Szachta P Rola alergii pokarmowej IgG-zależnej w patogenezie zmian skórnych Dermatologia Praktyczna 6/2013



  1. Yamaguchi N et al. Gastrointestinal Candida colonisation promotes sensitisation against food antigens by affecting the mucosal barrier in mice. Gut. 2006 Jul;55(7):954-60 IF= 14,66
  2. Faux, J A et al. Comparison of specific IgG antibody levels to the cell wall mannan of Candida albicans in normal individuals and in patients with primary antibody deficiency. J Immunol Methods 1992; 153, 167 – 172
  3. McHugh T M et al. Development of a microsphere based fluorescent immunoassay and it comparison to an enzyme immunoassay for the detection of antibodies to three preparations of Candida albicans J Immunol Methods 1989 116, 213-219
  4. Burnie J P et al. Outbreak of systemic Candida albicans  in intensive care unit caused by cross infection. Brit Med J 1985; 290, 746-748
  5. Ray TL Fungal infections in the immuno-compromised host. Med Clin N America 1980; 64, 955 – 968


Stres Oksydacyjny



  1. Macciò A et al.  Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients.  Journal of Cellular and Molecular Medicine, 13 (9B): 3951-3959, 2009.
  2. Mantovani G et al. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: Correlation with inflammatory and oxidative stress markers. The Oncologist, 13: 1296-1305, 2008.
  3. Mantovani G et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.  Nutrition 24: 305-313, 2008.
  4. Dragan S et al. Role of Multi-Component functional foods in the complex treatment of patients with advanced breast cancer.  Rev. Med. Chir. Soc. Med. Nat., Iasi, 111 (4): 877-884, 2007.
  5. Mantovani G et al. An Innovative treatment Approach for Cancer-related Anorexia/cachexia and Oxidative Stress: Background and Design of an Ongoing, Phase III, Randomized Clinical Trial. Supportive Cancer Therapy 4(3): 163-167, 2007.
  6. Mantovani G et al. Phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.  Cancer Epidemiol Biomarkers Prev 15(5): 1030-1034, 2006.
  7. Gramignano G et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22: 136-145, 2006.
  8. Macciò A et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 106 (1): 362-367, 2005.
  9. Mantovani G et al. Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment.  Cancer Epidemiol Biomarkers Prev 13: 1651-1659, 2004.
  10. Mantovani G et al. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.  J Exp Ther Oncol 3: 205-219, 2003.

Choroby sercowo-naczyniowe

  1. Hsieh CY et al. Effects of chronic 4-n-nonylphenol treatment on aortic vasoconstriction and vasorelaxation in rats. Archives in Toxicology 83: 941-946, 2009.
  2. Harris MT et al.Free oxygen radicals in whole blood correlate strongly with high-sensitivity C-reactive protein. Journal of Clinical Lipidology, 1: 593-598, 2007.
  3. Mercuro G et al. Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers. The Oncologist, 12 (9): 1124-1133, 2007.
  4. Piras A et al. Early Strain Rate impairment during treatment with epirubicin is associated with high levels of reactive oxygen species. European Heart Journal, 28 (Abstract Supplement), Abstract P2824 pp. 472-473, 2007.
  5. Riccioni G et al. Relationship between Oxidative Stress parameters and Atherosclerotic Carotid plaque. World Conference of Stress. 23-26 August, Budapest, Hungary, 2007.
  6. Abramson JL et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease.  Atherosclerosis 178: 115-121, 2005.


Choroby metaboliczne i cukrzyca

  1. Pavlatou MG et al. FORT and FORD: 2 simple and rapid assays in the evaluation of oxidative stress in patients with type 2 diabetes mellitus.  Metabolism Clinical and Experimental (in press), 2009.
  2. Lundström P et al. Oxidative Stress Related to Body Fat in Women. ACC.07, American College of Cardiology, 56th Annual Scientific Session, New Orleans, March 24-27, 2007.


Choroby infekcyjne i o podłożu zapalnym

  1. Sblendorio V, Palmieri B, Tesini EMC; Vandelli C. Oxidative status in Chronic Liver Disease.  World Conference of Stress. 23-26 August, Budapest, Hungary, 2007.
  2. Sblendorio V, Cannoletta M, Palmieri B, Cagnacci A. Menopause and Oxidative Stress: Effect of methyltetrahydrofolate Supplementation. World Conference of Stress. 23-26 August, Budapest, Hungary, 2007.


Choroby neurodegeneracyjne

  1. Burdi R et al. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of alarge array of in vivo and ex vivo tests. Journal of Applied Physiology 106: 1311-1324, 2009.
  2. Form and Parkinson’s Disease. Agnati L.F. and Leo G. Sect. of Physiology, Dept. of Biochemical Sciences, University of Modena and Reggio Emilia, Italy, 2002.



  1. Yoo JH et al. Oxidative status in iron-deficiency anemia.  Journal of Clinical Laboratory Analysis 23: 319-323, 2009.
  2. Yoo JH et al. Oxidative status in iron-deficiency anemia.  International Journal of Laboratory Hematology 30 (S1-Special Issue: Abstracts of the XXIst International Symposium on Technology Innovations in Laboratory Hematology): 137-138 (Abstract 802), 2008.
  3. Papastamataki M et al. FORT and FORD two novel assays for the assessment of oxidative stress in patients with thalassemia intermedia and sickle cell disease.  Haematologica, 92, Supplement no. 1, Abstract 0806 pp.301-302, June 2007.


Zaburzenia płodności

  1. Giulini S et al. Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele.  Reproductive BioMedicine Online 18 (5): 617-621, 2009.



  1. Changes of Reactive Oxygen Species (ROS) in Infants after Supplementary Surfactant. Parmigiani S. J Perinat Med 34 (Suppl. I) – Advances in Perinatal Medicine – 5th, 2006.
  2. C-Reactive protein versus reactive oxygen species in infants. Parmigiani S and Bevilacqua G. J Perinat Med 33 (Suppl 1), 2005.
  3. Parmigiani S and Bevilacqua G Reactive oxygen species (ROS) after surfactant administration in premature infants. 20th International Workshop on Surfactant Replacement, Belfast, 2-5 June, 2005.
  4. Parmigiani S et al. Determination of Reactive Oxygen Species: Evaluation of a Simple Colorimetric Method.  J Perinat Med 31 (Suppl 1): pp-264, 6th World Congress of Perinatal Medecine, 2003.

Choroby układu oddechowego

  1. Dal Negro RW et al. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. Therapeutic Advances in Respiratory Diseases , 2(5): 271-277, 2008.
  2. Erdosteine: Antitussive and Anti-inflammatory Effects. Dal Negro RW. Lung 186 (Suppl 1): S70-S73, 2008.
  3. Dal Negro RW et al. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: A controlled study in current smokers with mild COPD. Pulmonary Pharmacology & Therapeutics, 21: 304-308, 2008.
  4. Dal Negro et al. Effects of montelukast 10 mg OD or placebo on blood ROS levels in current smokers: a controlled, randomised, double blind-study. European Respiratory Journal 22 (Suppl 45): pp. 101S, 13th ERS Annual Congress, 2003.
  5. C. Micheletto, M. Visconti. Indicatori Bed-side dello Stress Ossidativo.  UO Pneumologia, Ospedale Orlandi, Bussolengo, VR. Proceedings of the 6° ACCP Meeting (American College of Chest Physicians, Capitolo Italiano), Asma Bronchiale e BPCO: Obiettivi Rimedi Strategie, 22-24 Gennaio, Palazzo della Gran Guardia, Verona, Italy, 2003.
  6. Variabilità, Ripetibilità e Valori di Normalità delle Misure di Stress Ossidativo determinate mediante Form System. Visconti M, Micheletto C, Dal Negro RW. UO Pneumologia, Ospedale Orlandi, Bussolengo, VR. Proceedings from 6° ACCP Meeting (American College of Chest Physicians, Capitolo Italiano), Asma Bronchiale e BPCO: Obiettivi Rimedi Strategie, 22-24 Gennaio, Palazzo della Gran Guardia, Verona, Italy, 2003.
  7. Verduri A et al. Oxygen Free Radicals Measurement in Capillary Blood in Healthy Subjects, Smokers and COPD Patients. Dip. Malattie Respiratorie, Università degli Studi di Parma. Proceeding from 98th International Conference, American Thoracic Society, May 17-22, Atlanta, Georgia, USA, 2002.


  1. E. Raposio et al. A quantitative evaluation of the PEFS treatment by Thermotone Plus and oxidative stress level measurement. , U.O. 2th International Congress of Preventive Medicine and Healthy Aging, Milan, 13-14 April, 2007.

Medycyna alternatywna

  1. Zabala BE, Flichman JC. Oxidative Stress and Quantum Therapies. Quant Med Assoc, 33-35, 2005.
  2. Hyperacusis treatment with a combination of Laser therapy, Pulsed Electromagnetic Field Therapy and Reactive Oxygen Specimen Control. PA Mikael Backman, ALIR Forlag, 2004.


  1. Lewis NA et. al. Critical Difference and Biological Variation in Biomarkers of Oxidative Stress and Nutritional Status in Athletes. PLoS One. 2016 Mar 1;11(3):e0149927.



  1. Isolauri E. et al. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut, 2002. 50 Suppl 3: p. III54-9
  2. Reid, G et al. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol, 2003. 37(2): p. 105-18
  3. Guarner F, et al. Gut flora in health and disease. The Lancet, 2003. 361(9356): p. 512-519
  4. Isolauri E Probiotics in human disease. Am J Clin Nutr, 2001. 73(6): p. 1142S-1146S.
  5. Noverr MC and Huffnagle GB The ‚microflora hypothesis’ of allergic diseases. Clinical & Experimental Allergy, 2005. 35(12): p. 1511-1520
  6. Erdeve O et al.Saccharomyces boulardii and antibiotic-associated diarrhoea in children. Alimentary Pharmacology and Therapeutics, 2005. 21(12): p. 1508-1509.
  7. Camilleri M et al. Probiotics and Irritable Bowel Syndrome: Rationale, Putative Mechanisms, and Evidence of Clinical Efficacy. Journal of Clinical Gastroenterology, 2006. 40(3): p. 264-269.
  8. Jie Z et al. Studies on the effects of polydextrose intake on physiologic functions in Chinese people. Am J Clin Nutr, 2000. 72(6): p. 1503-1509
  9. Probert HM et al. Polydextrose, Lactitol, and Fructo-Oligosaccharide Fermentation by Colonic Bacteria in a Three-Stage Continuous Culture System. Appl. Environ. Microbiol., 2004. 70(8): p. 4505-4511
  10. Paganelli R et al. Probiotics and food-allergic diseases. Allergy, 2002. 57(s72): p. 97-99
  11. Klarin B et al. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Crit Care, 2005. 9(3): p. R285-93
  12. Topping DL and Clifton PM Short-Chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Nonstarch Polysaccharides. Physiol. Rev., 2001. 81(3): p. 1031-1064
  13. Rosberg-Cody E et al. Mining the microbiota of the neonatal gastrointestinal tract for conjugated linoleic acid-producing bifidobacteria. Appl Environ Microbiol, 2004. 70(8): p. 4635-41
  14. Leahy SC et al. Getting better with bifidobacteria. J Appl Microbiol, 2005. 98(6): p. 1303-15.
    16.Salminen, S.J., M. Gueimonde, and E. Isolauri, Probiotics that modify disease risk. J Nutr, 2005. 135(5): p. 1294-8.
  15. Wullt M et al. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis, 2003. 35(6-7): p. 365-7
  16. McFarland L. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol, 2006. 101(4): p. 812-22
  17. Kennedy R et al. Probiotics in IBD. Gut, 2001. 49(6): p. 873
  18. Guslandi M Probiotics in Crohn’s disease. Gut, 2001. 49(6): p. 873-4
  19. Niedzielin K et al. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol, 2001. 13(10): p. 1143-7
  20. Nobaek S et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. The American Journal of Gastroenterology, 2000. 95(5): p. 1231-1238
  21. Madden J The intestinal microbiota and probiotics in irritable bowel syndrome. Scandinavian Journal of Nutrition, 2004. 48(1): p. 32-36
  22. Drisko JC Probiotics in health maintenance and disease prevention. Altern Med Rev, 2003. 8(2): p. 143-55
  23. Klijn A et al. Lessons from the genomes of bifidobacteria. FEMS Microbiology Reviews, 2005. 29(3): p. 491-509
  24. Tuohy K et al. Using probiotics and prebiotics to improve gut health. Drug Discov Today, 2003. 8(15): p. 692-700
  25. Wong JM et al. Colonic Health: Fermentation and Short Chain Fatty Acids. Journal of Clinical Gastroenterology, 2006. 40(3): p. 235-243
  26. Forchielli M and Walker W The role of gut-associated lymphoid tissues and mucosal defence. Br J Nutr, 2005. 93 Suppl 1: p. S41-8
  27. Collins M et al. Deoxyribonucleic acid Homology studies of Lactobacillus casei, Lactobacillus paracasei, sp. Noc., subsp paracasei and subsp tolerans and Lactobacillus rhamnosus sp. International Journal of Systematic Bacteriology, 1989. 39(2): p. 105-108
  28. Marteau PR et al. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr, 2001. 73(2 Suppl): p. 430S-436S
  29. Salminen SJ et al. Probiotics that modify disease risk. J Nutr, 2005. 135(5): p. 1294-8.
  30. Kalliomaki M et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet, 2003. 361(9372): p. 1869-71
  31. Colombel J et al. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects. Lancet, 1987. 2(8549): p. 43
  32. Schell M et al. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci U S A, 2002. 99(22): p. 14422-7
  33. Furrie E et al.  Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, 2005. 54(2): p. 242-249


  1. Lu R et al.Affinity purification and partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human brain. J Neurochem. 2000 Jan;74(1):320-6.
  2. Fasano A et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000 Apr 29;355(9214):1518-9.
  3. Wang W et al. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000 Dec;113 Pt 24:4435-40.
  4. Watts T et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2916-21.
  5. Zhang D et al. Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients. Diabetes Res Clin Pract. 2014 Nov;106(2):312-8.
  6. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011 Jan;91(1):151-75
  7. Moreno-Navarrete JM et al. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One. 2012;7(5):e37160.
  8. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci. 2012 Jul;1258:25-33
  9. Jayashree B et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2014 Mar;388(1-2):203-10
  10. Sapone A et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. 2006 May;55(5):1443-9
  11. Pacifico L et al. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol. 2014 Dec 7;20(45):17107-14


Dzięki uprzejmości Cambidge Diagnostics sp. z o.o.